Pmv Pharmaceuticals, Inc. Financials

PMVP

Source SEC Filings (10-K/10-Q) Updated Sep 30, 2025 Currency USD FYE December

This page shows Pmv Pharmaceuticals, Inc. (PMVP) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 7 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Piotroski F-Score Weak

1/9

Pmv Pharmaceuticals, Inc. passes 1 of 9 financial strength tests. 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).

Earnings Quality Low Quality

0.87x

For every $1 of reported earnings, Pmv Pharmaceuticals, Inc. generates $0.87 in operating cash flow (-$51.3M OCF vs -$58.7M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Interest Coverage At Risk

-8.0x

Pmv Pharmaceuticals, Inc. earns $-8.0 in operating income for every $1 of interest expense (-$85.4M vs $10.7M). This narrow margin raises concern about the company's ability to service its debt if operating income declines.

Key Financial Metrics

Export CSV

Revenue

N/A

EBITDA

-$84.3M

YoY-6.9%

Pmv Pharmaceuticals, Inc.'s EBITDA was -$84.3M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 6.9% from the prior year.

Free Cash Flow

-$51.9M

YoY+8.3%

Pmv Pharmaceuticals, Inc. generated -$51.9M in free cash flow in fiscal year 2024, representing cash available after capex. This represents an increase of 8.3% from the prior year.

Net Income

-$58.7M

YoY+14.9%

Pmv Pharmaceuticals, Inc. reported -$58.7M in net income in fiscal year 2024. This represents an increase of 14.9% from the prior year.

EPS (Diluted)

$-1.14

YoY+20.8%

Pmv Pharmaceuticals, Inc. earned $-1.14 per diluted share (EPS) in fiscal year 2024. This represents an increase of 20.8% from the prior year.

Cash & Debt

$40.9M

YoY+8.4%

5Y CAGR-11.0%

Pmv Pharmaceuticals, Inc. held $40.9M in cash against $0 in long-term debt as of fiscal year 2024.

Dividends Per Share

N/A

Shares Outstanding

52M

YoY+1.0%

Pmv Pharmaceuticals, Inc. had 52M shares outstanding in fiscal year 2024. This represents an increase of 1.0% from the prior year.

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

N/A

R&D Spending

$58.5M

YoY+4.7%

5Y CAGR+23.0%

Pmv Pharmaceuticals, Inc. invested $58.5M in research and development in fiscal year 2024. This represents an increase of 4.7% from the prior year.

Share Buybacks

N/A

Capital Expenditures

$655K

YoY-31.9%

5Y CAGR+43.1%

Pmv Pharmaceuticals, Inc. invested $655K in capex in fiscal year 2024, funding long-term assets and infrastructure. This represents a decrease of 31.9% from the prior year.

PMVP Income Statement

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$58.5M+4.7%	$55.9M+7.5%	$52.0M+42.5%	$36.5M+52.5%	$23.9M+15.3%	$20.8M
SG&A Expenses	$26.9M+11.0%	$24.2M-3.2%	$25.1M+14.9%	$21.8M+98.0%	$11.0M+87.3%	$5.9M
Operating Income	-$85.4M-6.6%	-$80.1M-4.0%	-$77.0M-32.2%	-$58.3M-66.8%	-$34.9M-31.2%	-$26.6M
Interest Expense	$10.7M-4.6%	$11.2M+208.0%	$3.6M+707.8%	$449K-31.0%	$651K-50.0%	$1.3M
Income Tax	-$16.1M-805100.0%	$2K+122.2%	-$9K-139.1%	$23K+283.3%	$6K-25.0%	$8K
Net Income	-$58.7M+14.9%	-$69.0M+5.9%	-$73.3M-26.7%	-$57.8M-68.0%	-$34.4M-35.8%	-$25.4M
EPS (Diluted)	$-1.14+20.8%	$-1.44+10.6%	$-1.61-25.8%	$-1.28+46.7%	$-2.40	N/A

Metric	Q3'25	Q3'24	Q4'23	Q3'23	Q4'22	Q3'22	Q4'21	Q3'21
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$18.2M+7.5%	$16.9M	N/A	$13.6M	N/A	$13.7M	N/A	$9.2M
SG&A Expenses	$4.3M-12.7%	$4.9M	N/A	$6.0M	N/A	$5.7M	N/A	$5.9M
Operating Income	-$22.5M-2.9%	-$21.9M	N/A	-$19.6M	N/A	-$19.4M	N/A	-$15.1M
Interest Expense	$1.5M-43.4%	$2.6M	N/A	$3.0M	N/A	$1.1M	N/A	$102K
Income Tax	-$6K-108.1%	$74K	N/A	$4K	N/A	-$9K	N/A	$19K
Net Income	-$21.1M-9.5%	-$19.2M	N/A	-$16.6M	N/A	-$18.2M	N/A	-$15.0M
EPS (Diluted)	$-0.40-8.1%	$-0.37	N/A	$-0.34	N/A	$-0.40	N/A	$-0.33

PMVP Balance Sheet

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Total Assets	$191.3M-24.1%	$252.2M-6.7%	$270.3M-18.5%	$331.6M-9.3%	$365.5M+254.8%	$103.0M
Current Assets	$175.7M-15.3%	$207.4M-16.0%	$247.0M-18.0%	$301.3M-17.4%	$364.8M+257.3%	$102.1M
Cash & Equivalents	$40.9M+8.4%	$37.7M-65.2%	$108.3M-37.2%	$172.5M-52.3%	$361.4M+393.2%	$73.3M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$15.2M-42.5%	$26.5M+9.0%	$24.3M+5.5%	$23.0M+259.0%	$6.4M-96.3%	$173.5M
Current Liabilities	$14.4M+2.4%	$14.0M+29.5%	$10.8M-11.4%	$12.2M+90.6%	$6.4M+41.7%	$4.5M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$176.1M-22.0%	$225.7M-8.3%	$246.0M-20.3%	$308.6M-14.1%	$359.1M+609.6%	-$70.5M
Retained Earnings	-$368.7M-18.9%	-$310.0M-28.6%	-$241.0M-43.7%	-$167.7M-52.6%	-$109.9M-45.7%	-$75.4M

Metric	Q3'25	Q3'24	Q4'23	Q3'23	Q4'22	Q3'22	Q4'21	Q3'21
Total Assets	$133.8M-30.0%	$191.3M-24.1%	$252.2M-3.4%	$261.0M-3.4%	$270.3M-5.1%	$285.0M-14.0%	$331.6M-3.7%	$344.2M
Current Assets	$132.4M-24.6%	$175.7M-15.3%	$207.4M+1.0%	$205.3M-16.9%	$247.0M-6.9%	$265.2M-12.0%	$301.3M-3.9%	$313.6M
Cash & Equivalents	$36.3M-11.1%	$40.9M+8.4%	$37.7M-27.6%	$52.1M-51.9%	$108.3M+8.5%	$99.8M-42.1%	$172.5M-2.4%	$176.6M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$12.8M-15.5%	$15.2M-42.5%	$26.5M+13.0%	$23.4M-3.6%	$24.3M+2.1%	$23.8M+3.4%	$23.0M+19.7%	$19.2M
Current Liabilities	$12.3M-14.4%	$14.4M+2.4%	$14.0M+30.9%	$10.7M-1.1%	$10.8M-7.1%	$11.7M-4.6%	$12.2M+42.7%	$8.6M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$121.0M-31.3%	$176.1M-22.0%	$225.7M-5.0%	$237.6M-3.4%	$246.0M-5.8%	$261.2M-15.4%	$308.6M-5.0%	$324.9M
Retained Earnings	-$428.4M-16.2%	-$368.7M-18.9%	-$310.0M-5.4%	-$294.2M-22.1%	-$241.0M-8.7%	-$221.7M-32.2%	-$167.7M-12.3%	-$149.4M

PMVP Cash Flow Statement

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Operating Cash Flow	-$51.3M+7.9%	-$55.7M+12.7%	-$63.8M-36.9%	-$46.6M-42.2%	-$32.7M-48.4%	-$22.1M
Capital Expenditures	$655K-31.9%	$962K-88.0%	$8.0M+491.8%	$1.3M+811.5%	$148K+35.8%	$109K
Free Cash Flow	-$51.9M+8.3%	-$56.6M+21.1%	-$71.7M-49.7%	-$47.9M-45.7%	-$32.9M-48.3%	-$22.2M
Investing Cash Flow	$53.4M+205.6%	-$50.5M-3594.8%	-$1.4M+99.0%	-$143.6M-614.4%	$27.9M+763.9%	$3.2M
Financing Cash Flow	$313K-99.1%	$35.6M+3613.7%	$958K-52.6%	$2.0M-99.3%	$293.0M+374.0%	$61.8M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q3'25	Q3'24	Q4'23	Q3'23	Q4'22	Q3'22	Q4'21	Q3'21
Operating Cash Flow	-$19.8M-19.0%	-$16.7M-37.9%	-$12.1M+22.8%	-$15.7M-2.2%	-$15.3M+8.6%	-$16.8M-39.3%	-$12.0M+3.0%	-$12.4M
Capital Expenditures	-$1K-101.8%	$56K-71.6%	$197K+347.7%	$44K-97.3%	$1.6M-20.1%	$2.0M+682.4%	$262K-47.7%	$501K
Free Cash Flow	-$19.8M-18.6%	-$16.7M-36.1%	-$12.3M+21.8%	-$15.7M+7.4%	-$17.0M+9.8%	-$18.8M-53.0%	-$12.3M+4.7%	-$12.9M
Investing Cash Flow	$12.0M+55.3%	$7.7M+399.2%	-$2.6M+92.3%	-$33.6M-244.9%	$23.2M-21.3%	$29.5M+290.4%	$7.6M+1190.8%	-$693K
Financing Cash Flow	$0-100.0%	$172K-40.3%	$288K-99.1%	$33.1M+5948.5%	$548K+9033.3%	$6K-98.0%	$295K-4.5%	$309K
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

PMVP Financial Ratios

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	-30.7%-3.3pp	-27.4%-0.2pp	-27.1%-9.7pp	-17.4%-8.0pp	-9.4%+15.2pp	-24.6%
Current Ratio	12.22-2.6	14.78-8.0	22.80-1.9	24.66-32.2	56.91+34.3	22.57
Debt-to-Equity	0.09-0.0	0.12+0.0	0.10+0.0	0.07+0.1	0.02+2.5	-2.46
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q3'25	Q3'24	Q4'23	Q3'23	Q4'22	Q3'22	Q4'21	Q3'21
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	-15.7%-7.1pp	-8.6%	N/A	-6.4%	N/A	-6.4%	N/A	-4.4%
Current Ratio	10.76-1.5	12.22-2.6	14.78-4.4	19.16-3.6	22.80+0.1	22.75-1.9	24.66-12.0	36.62
Debt-to-Equity	0.11+0.0	0.09-0.0	0.12+0.0	0.100.0	0.100.0	0.09+0.0	0.07+0.0	0.06
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Similar Companies

Prelude Therapeutics Inc PRLD

$140.2M

Adlai Nortye Ltd. ANL

$350.9M

Mink Therapeutics, Inc. INKT

$51.8M

Applied Therapeutics APLT

$14.9M

Celularity Inc CELU

$36.5M

Frequently Asked Questions

Is Pmv Pharmaceuticals, Inc. profitable?

No, Pmv Pharmaceuticals, Inc. (PMVP) reported a net income of -$58.7M in fiscal year 2024.

What is Pmv Pharmaceuticals, Inc.'s earnings per share (EPS)?

Pmv Pharmaceuticals, Inc. (PMVP) reported diluted earnings per share of $-1.14 for fiscal year 2024. This represents a 20.8% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

What is Pmv Pharmaceuticals, Inc.'s EBITDA?

Pmv Pharmaceuticals, Inc. (PMVP) had EBITDA of -$84.3M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.

What is Pmv Pharmaceuticals, Inc.'s free cash flow?

Pmv Pharmaceuticals, Inc. (PMVP) generated -$51.9M in free cash flow during fiscal year 2024. This represents a 8.3% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Pmv Pharmaceuticals, Inc.'s operating cash flow?

Pmv Pharmaceuticals, Inc. (PMVP) generated -$51.3M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.

What are Pmv Pharmaceuticals, Inc.'s total assets?

Pmv Pharmaceuticals, Inc. (PMVP) had $191.3M in total assets as of fiscal year 2024, including both current and long-term assets.

What are Pmv Pharmaceuticals, Inc.'s capital expenditures?

Pmv Pharmaceuticals, Inc. (PMVP) invested $655K in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.

How much does Pmv Pharmaceuticals, Inc. spend on research and development?

Pmv Pharmaceuticals, Inc. (PMVP) invested $58.5M in research and development during fiscal year 2024.

How many shares does Pmv Pharmaceuticals, Inc. have outstanding?

Pmv Pharmaceuticals, Inc. (PMVP) had 52M shares outstanding as of fiscal year 2024.

What is Pmv Pharmaceuticals, Inc.'s current ratio?

Pmv Pharmaceuticals, Inc. (PMVP) had a current ratio of 12.22 as of fiscal year 2024, which is generally considered healthy.

What is Pmv Pharmaceuticals, Inc.'s debt-to-equity ratio?

Pmv Pharmaceuticals, Inc. (PMVP) had a debt-to-equity ratio of 0.09 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Pmv Pharmaceuticals, Inc.'s return on assets (ROA)?

Pmv Pharmaceuticals, Inc. (PMVP) had a return on assets of -30.7% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.

What is Pmv Pharmaceuticals, Inc.'s cash runway?

Based on fiscal year 2024 data, Pmv Pharmaceuticals, Inc. (PMVP) had $40.9M in cash against an annual operating cash burn of $51.3M. This gives an estimated cash runway of approximately 10 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Pmv Pharmaceuticals, Inc.'s Piotroski F-Score?

Pmv Pharmaceuticals, Inc. (PMVP) has a Piotroski F-Score of 1 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Pmv Pharmaceuticals, Inc.'s earnings high quality?

Pmv Pharmaceuticals, Inc. (PMVP) has an earnings quality ratio of 0.87x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Pmv Pharmaceuticals, Inc. cover its interest payments?

Pmv Pharmaceuticals, Inc. (PMVP) has an interest coverage ratio of -8.0x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.